Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
clinical trial data
Biotech
AstraZeneca drops MASH drug over disappointing data
AstraZeneca has ended work on one of its drugs for fatty liver disease after viewing disappointing data from a phase 2 study.
James Waldron
Nov 6, 2025 5:21am
BridgeBio's calcium deficiency candidate scores phase 3 win
Oct 29, 2025 7:00am
Jupiter Endovascular's catheter platform shows positive results
Oct 28, 2025 10:00am
Zenas autoimmune drug prompts 95% drop in lesions in MS study
Oct 27, 2025 9:25am
Inhibrx intends FDA submission after phase 2 bone cancer win
Oct 24, 2025 6:40am
Alector halves staff after GSK-partnered antibody fails in ph. 3
Oct 22, 2025 11:23am
